Last reviewed · How we verify
NCT05243290
Nicotinamide Riboside Clinical Trial for GWI
NA trial testing Nicotinamide Riboside in Gulf War Illness in 52 participants. Currently enrolling.
30 April 2025
Quick facts
| Lead sponsor | Roskamp Institute Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 52 |
| Start date | 13 April 2022 |
| Primary completion | 30 April 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Nicotinamide Riboside — full drug profile →
- Placebo
Conditions studied
- Gulf War Illness — all drugs for Gulf War Illness →
Sponsor
Roskamp Institute Inc.
Who can join
Adults 47 to 70, any sex, with Gulf War Illness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05243290
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nicotinamide Riboside
Trials testing the same drug.
- NCT06587945 — Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment · Phase 4 · recruiting
- NCT06991712 — Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients · Phase 2 · recruiting
- NCT07073352 — ACEs, SIRT1, and Premature Vascular Aging in Humans · NA · recruiting
- NCT06032923 — Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabo · Phase 1, PHASE2 · recruiting
- NCT06044935 — Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate · NA · recruiting
Other recruiting trials for Gulf War Illness
Currently open trials in the same condition.
- NCT05820893 — Resistant Potato Starch to Alleviate GWI · Phase 2 · recruiting
- NCT05367245 — Ca-Mg Butyrate in GWI · Phase 2 · recruiting
- NCT05972291 — Mechanisms of Gulf War Illness · NA · recruiting
- NCT05375812 — NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH) · recruiting
- NCT05675878 — Confirmation of Diet as a Treatment for Gulf War Illness · Phase 3 · recruiting
Other Roskamp Institute Inc. trials
Trials by the same sponsor.
- NCT06883227 — Investigating Health Impacts of Exposure to Harmful Algal Blooms · recruiting
- NCT05736146 — Validating Gulf War Illness Blood Biomarkers · recruiting
- NCT05252949 — OEA for Targeting Lipid Metabolism in GWI · NA · completed
- NCT03974399 — BDNF Levels After Bacopa · NA · completed
- NCT03082638 — Identification of Gulf War Illness (GWI) Biomarkers · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05243290 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Roskamp Institute Inc.
- Last refreshed: 24 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05243290.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing